Physician Views: Will US cardiologists embrace Farxiga for heart failure?

Last week, the FDA expanded approval of the SGLT-2 inhibitor Farxiga to include treatment of adults suffering from heart failure with reduced ejection fraction (HFrEF), regardless of whether they have type 2 diabetes.

Some analysts have described this new indication as a multi-billion dollar opportunity for AstraZeneca, which markets Farxiga. A previous Physician Views poll we ran last September – in response to positive Phase III data from the DAPA-HF study – demonstrated considerable enthusiasm among cardiologists.

With US approval now granted, we are snap-polling US cardiologists to ascertain their awareness of Farxiga as a heart failure treatment, evaluate its clinical data and assess how it may be used in relation to Novartis' Entresto.

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

_______________

Q. The SGLT-2 inhibitor, Farxiga (dapagliflozin) has been approved by the FDA to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type-2 diabetes.

Approval is based on positive results from the landmark Phase III DAPA-HF trial, which showed Farxiga achieved a statistically significant and clinically meaningful reduction of CV death or hospitalisation for heart failure (HF), compared to placebo.

Are you aware of Farxiga and its demonstrated efficacy in the DAPA-HF study?

Yes

No

_____________ 

Q. The DAPA-HF trial showed that Farxiga, in addition to standard of care, reduced the risk of the composite outcome of CV death or the worsening of HF versus placebo by 26% (absolute risk reduction [ARR] = 5% [event rate/100 patient years: 11.6 versus 15.6, respectively]) in patients with HFrEF. During the trial duration, one CV death or hospitalisation for HF or an urgent visit associated with HF could be avoided for every 21 patients treated with Farxiga.

Fifty-five (55) percent of patients enrolled in the DAPA-HF study did not have type 2 diabetes. The safety profile of Farxiga in the DAPA-HF trial was consistent with the well-established safety profile of the medicine.

Are these data compelling enough to make you prescribe Farxiga?

Yes

No

_____________ 

Q. Would you consider the data for Farxiga from the DAPA-HF trial to be practice changing?

Yes

No

_____________ 

Q. Twelve months from now, to approximately what percentage of heart failure with reduced ejection fraction patients under your care do you estimate you will prescribe Farxiga to?

___%

_____________ 

Q. Do you anticipate that your future use of Farxiga will materially reduce your use of Entresto (sacubitril-valsartan)?

Yes

No

To read more Physician Views articles, click here.